Financing round reflects confidence in potential of innovative nanotherapies
Using nanoparticles to transport active ingredients to diseased organs — with this concept and the latest preclinical study results, SmartDyeLivery GmbH convinced its investors to invest a seven-figure sum in this funding round. The lead investor, bm‑t beteiligungsmanagement thüringen gmbh (bm|t), as well as a private investor from the existing consortium invested in order to enable the further growth of the innovative company from Jena.
“We are delighted with the development results achieved and are very grateful for the continued trust of our investors — especially in the current environment with unforeseen global challenges,” explains CEO Dr. Marc Lehmann. “The latest results from the non-clinical registration studies make it clear that the company is on the right track with the first application of the platform technology for septic liver failure,” said Stefan Jahn, Senior Investment Manager at bm|t. The new capital will be used to prepare and execute the first-in-man study.
SmartDyeLivery GmbH, based in Jena, Germany, is developing a universal platform technology based on functionalized nanoparticles that can be used to transport drugs or other cargoes to the desired organ in a targeted manner. The company´s aim is to provide new therapeutic options for diseases that were previously untreatable or difficult to treat. The innovative, proprietary technology can also be used for diagnostic or theranostic applications. For more information, please visit www.smartdyelivery.de/en
bm t beteiligungsmanagement thüringen gmbh (bm|t), headquartered in Erfurt, is the first address for venture capital investments in Thüringen, Germany. bm|t currently manages nine investment funds with a total volume of EUR 350 million and invests in innovative companies with strong growth potential across all industries and all phases of the company life cycle. More information about bm|t is available at www.bm‑t.com